{"id":20224,"date":"2024-04-22T16:22:37","date_gmt":"2024-04-22T10:52:37","guid":{"rendered":"https:\/\/www.fitterfly.com\/blog\/?p=20224"},"modified":"2024-04-22T18:59:00","modified_gmt":"2024-04-22T13:29:00","slug":"exploring-dtx-in-cardiovascular-disease-via-fitterflys-expert-discussion","status":"publish","type":"post","link":"https:\/\/www.fitterfly.com\/blog\/exploring-dtx-in-cardiovascular-disease-via-fitterflys-expert-discussion\/","title":{"rendered":"Exploring DTx in Cardiovascular Disease via Fitterfly\u2019s Expert Discussion"},"content":{"rendered":"

Digital therapeutics (DTx) is emerging as an innovative tool for delivering evidence-based therapeutic interventions for various medical conditions, including <\/span>cardiovascular diseases, diabetes, gastrointestinal issues, neurological conditions, cancer, addiction, and genitourinary issues. It delivers high-quality software programs to prevent, manage, or treat these conditions.<\/p>\n

To explore the potential of DTx in cardiovascular disease management, Fitterfly hosted a captivating webinar led by Dr Vivek Baliga<\/strong> [MBBS MRCP PhD MBA PGDLM, Consultant Physician and Cardiologist; Director, Baliga Diagnostics] and Dr Manthan Mehta<\/a> <\/strong>(Program Head for Hypertension & CV Health, Fitterfly). We bring about the focal points of this webinar, in case you missed the event.<\/span><\/p>\n

\"Speakers

Fig 1: Speakers at the Fitterfly\u2019s Webinar<\/span><\/i><\/p>\n

Global Burden of Cardiovascular Disease<\/b><\/h2>\n

The American College of Cardiology has come out with shocking details in its latest 2023 report, stating that global <\/span>cardiovascular disease-related mortality has <\/span>increased from 12.4 million in 1990 to 19.8 million in 2022<\/span><\/a>. Moreover, Eastern European countries demonstrate the maximum age-standardised total CVD deaths at 553 deaths per 100,000, whereas Australia registered the minimum age-standardised total CVD mortality at 122.5 deaths per 100,000 individuals. The report further pointed out that ischemic heart disease is the leading cause of <\/span>cardiovascular disease mortality at 108.8 deaths per 100,000 people.<\/span><\/p>\n

Role of DTx in Cardiovascular Disease Management<\/b><\/h2>\n

Sepah et al.<\/span><\/i> pioneered the concept of<\/span> \u201cdigital therapeutics\u201d<\/span><\/a> in their peer-reviewed publication and formally defined it as \u201cevidence-based behavioral treatments delivered online that can increase accessibility and effectiveness of healthcare.\u201d Physicians may prescribe DTx interventions independently or in combination with medications, devices, or other therapies to optimise patient care and health outcomes.<\/span><\/p>\n

The role of digital therapeutics in<\/span> cardiovascular diseases (CVD) is multifaceted, as it offers personalised interventions tailored to individual patient needs and real-time data collection and analysis to facilitate remote monitoring. These interventions are expected to control blood pressure, manage dyslipidemia, and reduce atherosclerotic cardiovascular disease risk. They prompt healthcare professionals to mediate promptly when necessary, potentially reducing the risk of cardiovascular events and improving outcomes.<\/span><\/p>\n

AHA\u2019s Life\u2019s Essential 8 Checklist<\/strong><\/h2>\n

The <\/span>American Heart Association <\/span><\/a>recommends 8 crucial measures for improving and maintaining cardiovascular health. They are:<\/span><\/p>\n